subtotal discectomy (sd; or, aggressive discectomy) and the latter, limited discectomy (ld; or, conservative discectomy). however, with either technique, the probability of post-operative reherniation exists and at a considerably high maximum of 21%, prompting patients to potentially undergo recurrent disk surgery. new treatments are emerging that are still in the beginning clinical trial phases. glucosamine injections may offer pain relief for some without precluding the use of more aggressive treatment options. adult stem cell or cell transplantation therapies for disc regeneration are in their infancy of development, but initial clinical trials have shown cell transplantation to be safe and initial observations suggest some beneficial effects for associated pain and disability. an optimal cell type, transplantation method, cell density, carrier, or patient indication remains to be determined. investigation into mesenchymal stem cell therapy knife-less fusion of vertebrae in the united states began in 2006 and a discgenics nucleus pulposus progenitor cell transplantation clinical trial has started as of 2018 in the united states and japan. researchers and surgeons have conducted clinical and basic science studies to uncover the regenerative capacity possessed by the large animal species involved (humans and quadrupeds) for potential therapies to treat the disease. some therapies, carried out by research laboratories in new york, include introduction of biologically engineered, injectable riboflavin cross-linked high density collagen (hdc-laden) gels into disease spinal segments to induce regeneration, ultimately restoring functionality and structure to the two main inner and outer components of vertebral discs—anulus fibrosus and the nucleus pulposus. other animals degenerative disc disease can occur in other mammals besides humans. it is a common problem in several dog breeds, and attempts to remove this disease from dog populations have led to several hybrid breeds, such as the chiweenie.